Missouri Autism Centers of Excellence Collaborative (MACEC): SEED Early Development Study

摘要 本项目的重点是流行病学研究的延续 自闭症和发育障碍流行病学中心的能力 (CADDRE)网络与实施第三阶段研究的早期探索 发展。SEED研究正在进行的目标是确定自闭症的特征 行为表型及其相关的发育、医学和行为状况 患有自闭症。了解自闭症的遗传和环境风险因素。这个 本申请的目的如下：1.实施SEED研究的第三阶段 保留核心研究设计，并对其进行增强以提高招聘和 减少了一个新的中西部种子站点的数据收集协议。以下是 核心研究设计的各个方面将保留在第三阶段：a)病例对照研究 ASD病例组、非ASD病例组的多源确证设计 发展性残疾(DD)对照组和以人群为基础的(POP) 对照组，b)临床确认所有参与者的发育状况 使用标准化评估方案，以及c)收集临床、遗传和 环境数据。加强招聘工作将包括积极的后续行动 受邀参会者的程序。与此相比，数据收集将得到简化 阶段2，主要是取消儿科和新生儿病历摘要 所有三个参与者组和为DD对照组收集的缩减数据。 2.进一步增加种子总样本量，提高种子分析水平 通过获取完整数据来调查罕见暴露和ASD亚型的可能性 收集了125名ASD儿童、125名DD儿童和125名POP儿童的资料。 在所有预期的3期场地实现这些目标将增加种子ASD总量 向大约2000名儿童提供样本，这将加强对罕见疾病的检查 暴露和适度的关联可能与ASD的病因相关。

Abstract This project is a focused on the continuation of the epidemiological research capability of the Centers for Autism and Developmental Disabilities Epidemiology (CADDRE) network with implementation of Phase 3 of the Study to Explore Early Development. The ongoing objectives of the SEED study are to characterize the autism behavioral phenotype and associated developmental, medical and behavioral conditions of autism. and to understand the genetic and environmental risk factors of Autism. The aims of this application are as follows: 1. Implement a third Phase of the SEED study preserving the core study design with enhancements to improve recruitment and a reduction in the data collection protocol in a new Midwestern SEED site. The following aspects of the core study design will be preserved in Phase 3: a) a case-control study design with multiple- source ascertainment of an ASD case group, a non- ASD developmental disability (DD) comparison group and a population-based (POP) comparison group, b) clinical confirmation of developmental status of all participants using a standardized assessment protocol, and c) collection of clinical, genetic and environmental data. Recruitment enhancements will include active follow-up procedures for invited participants. Data collection will be streamlined, compared to Phase 2, primarily by eliminating pediatric and neonatal medical record abstraction for all three participant groups and curtailing data collected for the DD comparison group. 2. Further increase the total SEED pooled sample size to enhance SEED's analytic potential to investigate rare exposures and ASD subtypes by achieving complete data collection on 125 ASD children, 125 DD children and 125 POP children within our site. Reaching these targets at all anticipated Phase 3 sites will increase the total SEED ASD sample to approximately 2000 children which will enhance the examination of rare exposures and modest associations potentially relevant to the etiology of ASD.